CORAL GABLES, FL / ACCESSWIRE / August 8, 2018 / Healthcare and biotechnology have not faltered during recent weeks. No matter what announcements have come up regarding the potential trade war, stocks in this sector have continued to rally this summer. A number of mid and late-stage biotech stocks have begun reporting pivotal research progress that could help bolster more attention in the market.
In line with this, the iShares Biotechnology Index (IBB) has risen an impressive 8.9% this year, and the market for small, early-stage biotech stocks is even more active than the industry tracking index suggests. Here are 3 biotech stocks to watch as the second half of the year begins to heat up.
Market Cap: $96,832,678
This small-cap biotech company has put together a vast pipeline of treatments. Its more recent highlights center around the company's immuno-oncology platforms. Aside from announcing a private placement of convertible debentures for gross proceeds of $5,140,000, GT Biopharma has also begun to build a relationship to enhance its OXS-1550.
The company announced on July 19 a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota.
This Major Pharmaceutical Company will supply a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.
Shares of GT Biopharma are up 47% from July 10th lows to Monday's closing price.
More information On GT Biopharma, Click Here
Strongbridge Biopharma (NASDAQ: SBBP)
Market Cap: $204,905,993
This morning Strongbridge Biopharma plc announced top-line results from the multinational, pivotal Phase 3 SONICS study evaluating RECORLEV™ (levoketoconazole) for the treatment of endogenous Cushing's syndrome.
The company also reported second-quarter 2018 financial results. Achieved KEVEYIS net product sales of $4.3 million in the second quarter of 2018, a 187 percent increase compared to $1.5 million in the second quarter of 2017. Additionally, full-year 2018 KEVEYIS revenue guidance remains $18 - $20 million.
Shares of Array were up as much as 68.89% during pre-market trading on Tuesday
For More Information on Strongbridge Biopharma, Click Here
INSYS Therapeutics, Inc. (NASDAQ: INSY)
Market Cap: $490,829,212
Shares of INSYS have been in an uptrend for the better part of the last 3 trading sessions. The company announced today that it has reached an agreement in principle with the Department of Justice to settle the DOJ's civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.
"This is a very important step for our company to move forward and continue our transformative efforts to foster a compliant and ethical culture and to execute against our well-differentiated product pipeline, which we believe can bring value to patients globally," said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.
Since Monday's lows of $6.41, shares of INSYS are up by as much as 13.89% following an open of $7.30 per share.
For More Information On INSYS, Click Here
About MarijuanaStocks.com
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. An affiliate of MarijuanaStocks.com - MIDAM VENTURES LLC., a Florida Corporation that has been compensated $200,000.00 by GT Biopharma Inc. for a period beginning July 16, 2018, and ending August 16, 2018, to publicly disseminate information about (GTBP). We own zero shares. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Contact Information:
SOURCE: MarijuanaStocks.com
